KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• KalVista Pharmaceuticals, Inc. has received a consensus rating of "Moderate Buy" from ten brokerages, with one analyst recommending a sell, eight a buy, and one a strong buy.
• The company reported a loss of ($1.12) EPS for the last quarter, missing estimates, and revenue also fell short of expectations at $1.43 million.
• Several institutional investors have significantly increased their holdings in KalVista, including Ameriprise Financial, which raised its ownership by 2,258.6% during the second quarter.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $26.4286.

KALV has been the topic of several recent analyst reports. HC Wainwright boosted their target price on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. Leerink Partners boosted their target price on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, July 7th. JMP Securities boosted their target price on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a "market outperform" rating in a research note on Friday, September 12th. Needham & Company LLC restated a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 12th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a research note on Saturday, September 27th.

KalVista Pharmaceuticals Price Performance

KALV opened at $10.92 on Wednesday. KalVista Pharmaceuticals has a fifty-two week low of $7.30 and a fifty-two week high of $17.28. The firm's fifty day moving average price is $13.24 and its two-hundred day moving average price is $12.88. The company has a market capitalization of $551.68 million, a P/E ratio of -2.77 and a beta of -0.15.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings results on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.21). The business had revenue of $1.43 million for the quarter, compared to analysts' expectations of $1.97 million. On average, equities research analysts expect that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

Insider Transactions at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 2,942 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.22, for a total value of $38,893.24. Following the completion of the transaction, the insider directly owned 119,841 shares of the company's stock, valued at $1,584,298.02. The trade was a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Benjamin L. Palleiko sold 10,940 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.22, for a total value of $144,626.80. Following the completion of the transaction, the chief executive officer directly owned 386,858 shares of the company's stock, valued at $5,114,262.76. This represents a 2.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,856 shares of company stock valued at $374,910 over the last ninety days. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KALV. Ameriprise Financial Inc. raised its holdings in shares of KalVista Pharmaceuticals by 2,258.6% in the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company's stock valued at $10,685,000 after buying an additional 905,053 shares during the last quarter. Parkman Healthcare Partners LLC bought a new stake in KalVista Pharmaceuticals during the 1st quarter worth about $8,698,000. Woodline Partners LP raised its holdings in KalVista Pharmaceuticals by 25.5% during the 1st quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company's stock worth $18,666,000 after purchasing an additional 329,068 shares during the last quarter. Panagora Asset Management Inc. raised its holdings in KalVista Pharmaceuticals by 307.0% during the 2nd quarter. Panagora Asset Management Inc. now owns 292,593 shares of the specialty pharmaceutical company's stock worth $3,308,000 after purchasing an additional 220,697 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust raised its holdings in KalVista Pharmaceuticals by 26.4% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company's stock worth $8,693,000 after purchasing an additional 160,759 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.